Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell

Key Points

• Wall Street Zen downgraded BioAge Labs (NASDAQ:BIOA) from a "hold" to a sell rating in a research note issued Saturday.
• Despite that downgrade, four analysts rate the stock "Buy" vs. one "Sell," leaving a MarketBeat consensus of Moderate Buy with an average price target of $46.25.
• Shares opened at $17.05 (52-week range $3.67–$24.00; market cap ~$756.7M); the company reported Q1 EPS of -$0.72 (beat estimates by $0.11) but has negative margins and an expected -2.7 EPS for the year, and insider Paul D. Rubin sold 7,433 shares while insiders own 20.82%.

BioAge Labs (NASDAQ:BIOA - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.

Several other research analysts have also recently issued reports on BIOA. Needham & Company LLC initiated coverage on BioAge Labs in a research note on Friday, March 27th. They issued a "buy" rating and a $50.00 price objective on the stock. Morgan Stanley set a $23.00 price objective on BioAge Labs in a research note on Wednesday, February 4th. Oppenheimer initiated coverage on BioAge Labs in a research note on Wednesday, February 25th. They issued an "outperform" rating and a $60.00 price objective on the stock. Piper Sandler initiated coverage on BioAge Labs in a research note on Tuesday, January 27th. They issued an "overweight" rating on the stock. Finally, Citigroup increased their price objective on BioAge Labs from $15.00 to $52.00 and gave the stock a "buy" rating in a research note on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $46.25.

BioAge Labs Stock Down 1.1%

Shares of NASDAQ:BIOA opened at $17.05 on Friday. BioAge Labs has a 52-week low of $3.67 and a 52-week high of $24.00. The stock has a market cap of $756.68 million, a P/E ratio of -7.61 and a beta of 1.80. The business's 50 day moving average is $18.96 and its 200 day moving average is $14.66.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.11. BioAge Labs had a negative return on equity of 27.86% and a negative net margin of 896.11%.The company had revenue of $3.08 million for the quarter. On average, sell-side analysts anticipate that BioAge Labs will post -2.7 EPS for the current fiscal year.

Insider Transactions at BioAge Labs

In other BioAge Labs news, insider Paul D. Rubin sold 7,433 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total transaction of $139,368.75. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 20.82% of the company's stock.

Institutional Trading of BioAge Labs

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP bought a new stake in BioAge Labs during the 3rd quarter valued at $181,000. R Squared Ltd bought a new stake in BioAge Labs during the 3rd quarter valued at $154,000. Vontobel Holding Ltd. boosted its position in BioAge Labs by 36.4% during the 3rd quarter. Vontobel Holding Ltd. now owns 15,000 shares of the company's stock valued at $88,000 after acquiring an additional 4,000 shares in the last quarter. Strs Ohio boosted its position in BioAge Labs by 26.4% during the 4th quarter. Strs Ohio now owns 22,500 shares of the company's stock valued at $298,000 after acquiring an additional 4,700 shares in the last quarter. Finally, CWM LLC boosted its position in BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company's stock valued at $49,000 after acquiring an additional 1,053 shares in the last quarter.

BioAge Labs Company Profile

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.